# Antios Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antios-therapeutics

- Industry: Biotechnology
- Headquarters: Atlanta, US
- Website: www.antiostherapeutics.com
- Total disclosed funding: $122M
- Latest round: Series B (Nov 3, 2021)
- Investors on record: 19

## About

Based in New Jersey, US and founded in 2018 by Abel De La Rosa, Douglas Mayers and Idean Marvasty, Antios Therapeutics, Inc., (Antios) is a biopharmaceutical company that develops novel therapies to treat and cure Hepatitis B Virus (HBV) and other viral diseases. In 2021, Antios raised USD 96 million in series B funding led by new investor Soleus Capital Management, with participation from other new investors such as Adage Capital Management, Aisling Capital and Altium Capital among others.

The company’s product is a novel ASPIN (Active Site Polymerase Inhibitor Nucleotide) called ATI-2173 that targets the liver and is a potentially curative therapy for chronic Hepatitis B Virus. The company designed this drug to deliver 5’- monophosphate of clevudine to the liver where it is metabolized to the active 5’-triphosphate. This provides a potential HBV antiviral activity, improved pharmacokinetic profile for clinical use, reduced systemic exposure of clevudine, no toxic results to cells, the potential elimination of skeletal myopathy and off-treatment suppression of HBV DNA. 

ATI-2173, a descendant of clevudine, to be administered orally once daily, is a nucleotide that restrains all stages of DNA synthesis. Unlike traditional NA’s (Nucleoside Analogues) that inhibit viral replication one genome at a time, the company’s drug prohibits replication one polymerase at a time. Antios conducts research and development for chronic HBV infection. Current therapies including chain-terminating NA, result in viral replication in over 90% of patients upon discontinuing the treatment.  

In the future, the company plans to utilize the funding to support the development of the Phase 2 clinical program of ATI-2173 for HBV infections.

## Funding rounds

- Series B, Nov 3, 2021, $75M — Domain Associates, Fonds de Solidarité des Travailleurs du Québec, Aisling Capital, Adage Capital Management, Pontifax Venture Capital, Granite Point Capital Management, Altium Capital, GRA Venture Fund, CAM Capital, RA Capital Management, Delos Capital Partners, LifeSci Partners, EPIQ Capital Group, Soleus Capital, Sixty Degree Capital, Amzak Capital Management, GordonMD Global Investments, Lumira Ventures
- Series B, Apr 9, 2021, $32M — Domain Associates, Aisling Capital, Adage Capital Management, Pontifax Venture Capital, Granite Point Capital Management, Altium Capital, CAM Capital, RA Capital Management, Delos Capital Partners, LifeSci Partners, Soleus Capital, Sixty Degree Capital, Amzak Capital Management, Lumira Ventures
- Series A, Oct 31, 2018, $15M — Domain Associates, Fonds de Solidarité des Travailleurs du Québec, GRA Venture Fund, CAM Capital, Delos Capital Partners, Quantum Vista Capital, Sixty Degree Capital, Lumira Ventures

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B
- Fonds de Solidarité des Travailleurs du Québec — Series A, Series B
- GRA Venture Fund (https://capitalatlas.ai/funds/gra-venture-fund) — Series A, Series B
- CAM Capital — Series A, Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series A, Series B
- Quantum Vista Capital — Series A
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series A, Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- Adage Capital Management — Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Granite Point Capital Management — Series B
- Altium Capital — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series B
- EPIQ Capital Group — Series B
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series B